The Chhattisgarh health department is focused on maintaining high standards for the medicines available to its citizens. As part of these efforts, the department has issued a show-cause notice to M/s. Effi Parenterals, which could lead to the company being blacklisted for supplying substandard drugs.
The department follows a rigorous process to ensure drug quality. Before medicines are distributed to health institutions, samples from each batch are sent for testing to NABL-accredited laboratories. This process ensures that only medicines that meet the required quality standards are supplied to hospitals and clinics.
In the current case, Albendazole tablets IP 400 mg (Drug Code – D12) from batches PGT25451, PGT25450, PGT25480, and PGT25229, supplied by M/s. Effi Parenterals, were tested at the State Drug Testing and Research Laboratory, Raipur. The tests revealed that these batches did not meet the required standards. Consequently, the firm is facing potential blacklisting, and a show-cause notice has been issued. Additionally, the company must retrieve the failed batches from the drug warehouses.
It is important to note that the company had previously supplied 14 batches of the same medication, which had passed quality testing and were distributed to healthcare facilities.